ProtoKinetix Announces New President and Chief Executive Officer

ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTC:PKTX) (www.protokinetix.com) (the "Company" or "ProtoKinetix") announces that a cease trade order issued by the British Columbia Securities Commission was revoked effective as of the date of this news release. In connection with the revocation, the Company also announces that it has received and accepted the resignation of Mr. Ross Senior as a Director, President and Chief Executive Officer of the Company effective as of February 19, 2015. Mr. Clarence E. Smith has been appointed as the Company's new President and Chief Executive Officer.

ProtoKinetix further announces that it has moved its head office to 9176 South Pleasants Highway, St. Marys, West Virginia, USA 26170.

About ProtoKinetix

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

ON BEHALF OF THE BOARD OF DIRECTORS
PROTOKINETIX, INCORPORATED

Clarence E. Smith
President and Chief Executive Officer

Cautionary Statement Regarding Forward-Looking Information

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law, including statements regarding the potential treatments for which the Company's AAGPTM may be applied. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. More detailed information about potential factors that could affect financial results is included in the documents filed by the Company from time to time with the United States Securities Commission and with securities regulatory authorities in Canadian on SEDAR.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Contacts

ProtoKinetix:
Clarence E. Smith, 304-299-5070
President & Chief Executive Officer
[email protected]
 

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.